{
    "info": {
        "nct_id": "NCT03360721",
        "official_title": "A Phase 2, Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Metastatic Prostate Cancer Patients Evaluating a Predetermined Biomarker Signature",
        "inclusion_criteria": "* Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features\n* Presence of metastatic disease that can be biopsied by any methodology applicable\n* Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy (i.e., surgical or medical castration)\n* Serum testosterone level =< 50 ng/dL at the screening visit\n* Progressive disease defined as one or more of the following three criteria (NOTE: Patients who received an antiandrogen must demonstrate disease progression following discontinuation of antiandrogen):\n\n  * PSA progression defined by a minimum of two rising PSA levels with an interval of >= 1 weeks between each determination. The PSA value at the screening visit should be >= 2 ng/mL\n  * Soft tissue disease progression as defined by the Response Evaluation Criteria in Solid Tumors (RECIST)\n  * Bone disease progression defined by two or more new lesions on bone scan\n* Patients previously treated with chemotherapy must have no more than two prior chemotherapy regimens for the treatment of metastatic prostate cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Serum albumin >= 3.0 g/dL\n* Serum potassium >= 3.5 mmol/L\n* Estimated life expectancy of >= 6 months\n* Able to swallow the study drug and comply with study requirements\n* Willing and able to give informed consent\n* Tumor specimen obtained prior to treatment initiation by interventional radiology guided biopsy will be interrogated per immunohistochemistry (IHC) and features should be as follows for a patient to be eligible\n\n  * Overexpression of androgen receptor (AR)-C terminal and AR-N terminal and PTEN with lack of ARV7 expression along with and ki67 =<10%\n  * No combined RB loss and p53 mutation and\n  * No expression of neuroendocrine markers CD56 and chromogranin (all markers assessed by standardized IHC protocols)\n* Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug\n\n  * The methods must consist of a condom and the use of another barrier method (such as a diaphragm or cervical/vault caps) with a spermicidal agent. Your female partner can choose to use an intrauterine device or system (intrauterine device [IUD] or intrauterine system [IUS]) or use birth control pills, injections, or implants instead of a barrier method\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Known allergy to the study drugs or any of its components\n* Severe, concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated\n* Known metastases to the brain\n* Absolute neutrophil count < 1000/uL at the screening visit\n* Platelet count =< 100,000 x 10^9/uL at the screening visit\n* Hemoglobin < 9 g/dL at the screening visit at the screening visit\n* NOTE: patients may not have received any growth factors or blood transfusions within seven days of the hematologic laboratory values obtained at the screening visit\n* Total bilirubin (Tbili) > 1.5 times the upper limit of normal at the screening visit\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal at the screening visit\n* Creatinine (Cr) > 2 mg/dL at the screening visit\n* History of another malignancy within the previous 2 years with > 30 % probability of relapse other than curatively treated non-melanomatous skin cancer\n* Treatment with androgen receptor antagonists (bicalutamide, flutamide, nilutamide), 5-alpha reductase inhibitors (finasteride, dutasteride), estrogens, chemotherapy, or biologic therapy within 4 weeks of enrollment (day 1 visit)\n* Radiation therapy within 3 weeks (if single fraction of radiotherapy within 2 weeks) of enrollment (day 1 visit)\n* Planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery\n* Structurally unstable bone lesions suggesting impending fracture\n* History of seizure or any condition that may increase the patient's seizure risk. Also, history of loss of consciousness or transient ischemic attack within 12 months of day 1\n* Clinically significant cardiovascular disease including:\n\n  * Myocardial infarction within 6 months\n  * Uncontrolled angina within 6 months\n  * Congestive heart failure New York Heart Association (NYHA) class 3 or 4 in the past, or history of anthracycline or anthracenedione (mitoxantrone) treatment, unless a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within three months results in a left ventricular ejection fraction that is >= 45%\n  * History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)\n  * Prolonged corrected QT interval by the Fridericia correction formula (QTcF) on the screening electrocardiogram (ECG) > 470 msec\n  * History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place\n  * Hypotension (systolic blood pressure < 86 millimeters of mercury or bradycardia with a heart rate of < 50 beats per minute on any ECG taken at the screening visit\n  * Bradycardia with a heat rate of < 50 beats per minutes in the screening ECG, unless pharmaceutically induced and reversible\n  * Chronically uncontrolled hypertension as indicated by consistently elevated resting blood pressure (systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg) during screening\n* Have used or plan to use from 30 days prior to enrollment (day 1 visit) through the end of the study the following medications known to lower the seizure threshold:\n\n  * Aminophylline/theophylline\n  * Atypical antipsychotics (e.g., clozapine, olanzapine, risperidone, ziprasidone)\n  * Bupropion\n  * Insulin\n  * Lithium\n  * Pethidine\n  * Phenothiazine antipsychotics (e.g., prochlorperazine [compazine], chlorpromazine, mesoridazine, thioridazine)\n  * Tricyclic and tetracyclic antidepressants (e.g., amitriptyline, desipramine, doxepin, imipramine, maprotiline, mirtazapine)\n* Prior use of ketoconazloe, enzalutamide, abiraterone or apalutamide or participation in a previous clinical trial of ketoconazloe,enzalutamide, abiraterone or apalutamide unless within the neoadjuvant setting\n* Use of an investigational agent within 4 weeks of enrollment (day 1)\n* Gastrointestinal disorder affecting absorption (e.g., gastrectomy)\n* Major surgery within 4 weeks prior to enrollment (day 1)\n* History of significant bleeding disorder unrelated to cancer, including:\n\n  * Diagnosed congenital bleeding disorders (e.g., von Willebrand's' disease)\n  * Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)\n  * History of gastrointestinal (GI) bleeding within one year\n* Known active or symptomatic viral hepatitis or chronic liver disease\n* Known history of pituitary or adrenal dysfunction\n* Baseline moderate and severe hepatic impairment (Child Pugh class B & C)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Presence of metastatic disease that can be biopsied by any methodology applicable",
            "criterions": [
                {
                    "exact_snippets": "Presence of metastatic disease",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "can be biopsied by any methodology applicable",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "biopsiable",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed adenocarcinoma of the prostate",
                    "criterion": "adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "without neuroendocrine differentiation",
                    "criterion": "neuroendocrine differentiation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "without ... small cell features",
                    "criterion": "small cell features",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum testosterone level =< 50 ng/dL at the screening visit",
            "criterions": [
                {
                    "exact_snippets": "Serum testosterone level =< 50 ng/dL at the screening visit",
                    "criterion": "serum testosterone level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progressive disease defined as one or more of the following three criteria (NOTE: Patients who received an antiandrogen must demonstrate disease progression following discontinuation of antiandrogen):",
            "criterions": [
                {
                    "exact_snippets": "Progressive disease defined as one or more of the following three criteria",
                    "criterion": "progressive disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who received an antiandrogen must demonstrate disease progression following discontinuation of antiandrogen",
                    "criterion": "disease progression after antiandrogen discontinuation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PSA progression defined by a minimum of two rising PSA levels with an interval of >= 1 weeks between each determination. The PSA value at the screening visit should be >= 2 ng/mL",
            "criterions": [
                {
                    "exact_snippets": "PSA progression defined by a minimum of two rising PSA levels with an interval of >= 1 weeks between each determination",
                    "criterion": "PSA progression",
                    "requirements": [
                        {
                            "requirement_type": "number of rising PSA levels",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "interval between PSA determinations",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "The PSA value at the screening visit should be >= 2 ng/mL",
                    "criterion": "PSA value at screening visit",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "ng/mL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Soft tissue disease progression as defined by the Response Evaluation Criteria in Solid Tumors (RECIST)",
            "criterions": [
                {
                    "exact_snippets": "Soft tissue disease progression as defined by the Response Evaluation Criteria in Solid Tumors (RECIST)",
                    "criterion": "soft tissue disease progression",
                    "requirements": [
                        {
                            "requirement_type": "progression_status",
                            "expected_value": "progression as defined by RECIST"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bone disease progression defined by two or more new lesions on bone scan",
            "criterions": [
                {
                    "exact_snippets": "Bone disease progression defined by two or more new lesions on bone scan",
                    "criterion": "bone disease progression",
                    "requirements": [
                        {
                            "requirement_type": "definition",
                            "expected_value": "two or more new lesions on bone scan"
                        }
                    ]
                },
                {
                    "exact_snippets": "two or more new lesions on bone scan",
                    "criterion": "new bone lesions",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lesions"
                            }
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "bone scan"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients previously treated with chemotherapy must have no more than two prior chemotherapy regimens for the treatment of metastatic prostate cancer",
            "criterions": [
                {
                    "exact_snippets": "Patients previously treated with chemotherapy must have no more than two prior chemotherapy regimens for the treatment of metastatic prostate cancer",
                    "criterion": "number of prior chemotherapy regimens for metastatic prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "regimens"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum potassium >= 3.5 mmol/L",
            "criterions": [
                {
                    "exact_snippets": "Serum potassium >= 3.5 mmol/L",
                    "criterion": "serum potassium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3.5,
                                "unit": "mmol/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Estimated life expectancy of >= 6 months",
            "criterions": [
                {
                    "exact_snippets": "Estimated life expectancy of >= 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum albumin >= 3.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Serum albumin >= 3.0 g/dL",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy (i.e., surgical or medical castration)",
            "criterions": [
                {
                    "exact_snippets": "Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy (i.e., surgical or medical castration)",
                    "criterion": "androgen deprivation therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "ongoing"
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "GnRH analogue",
                                "orchiectomy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Able to swallow the study drug and comply with study requirements",
            "criterions": [
                {
                    "exact_snippets": "Able to swallow the study drug",
                    "criterion": "ability to swallow study drug",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "comply with study requirements",
                    "criterion": "ability to comply with study requirements",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing and able to give informed consent",
            "criterions": [
                {
                    "exact_snippets": "Willing ... to give informed consent",
                    "criterion": "willingness to give informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "able to give informed consent",
                    "criterion": "ability to give informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumor specimen obtained prior to treatment initiation by interventional radiology guided biopsy will be interrogated per immunohistochemistry (IHC) and features should be as follows for a patient to be eligible",
            "criterions": [
                {
                    "exact_snippets": "Tumor specimen obtained prior to treatment initiation by interventional radiology guided biopsy",
                    "criterion": "tumor specimen",
                    "requirements": [
                        {
                            "requirement_type": "obtained prior to treatment initiation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method of acquisition",
                            "expected_value": "interventional radiology guided biopsy"
                        }
                    ]
                },
                {
                    "exact_snippets": "interrogated per immunohistochemistry (IHC)",
                    "criterion": "tumor specimen",
                    "requirements": [
                        {
                            "requirement_type": "interrogation method",
                            "expected_value": "immunohistochemistry (IHC)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No expression of neuroendocrine markers CD56 and chromogranin (all markers assessed by standardized IHC protocols)",
            "criterions": [
                {
                    "exact_snippets": "No expression of neuroendocrine markers CD56 and chromogranin",
                    "criterion": "neuroendocrine marker expression (CD56, chromogranin)",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "markers assessed",
                            "expected_value": [
                                "CD56",
                                "chromogranin"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No combined RB loss and p53 mutation and",
            "criterions": [
                {
                    "exact_snippets": "No combined RB loss and p53 mutation",
                    "criterion": "RB loss and p53 mutation",
                    "requirements": [
                        {
                            "requirement_type": "combined presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Overexpression of androgen receptor (AR)-C terminal and AR-N terminal and PTEN with lack of ARV7 expression along with and ki67 =<10%",
            "criterions": [
                {
                    "exact_snippets": "Overexpression of androgen receptor (AR)-C terminal",
                    "criterion": "androgen receptor (AR)-C terminal expression",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": "overexpression"
                        }
                    ]
                },
                {
                    "exact_snippets": "Overexpression of ... AR-N terminal",
                    "criterion": "androgen receptor (AR)-N terminal expression",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": "overexpression"
                        }
                    ]
                },
                {
                    "exact_snippets": "Overexpression of ... PTEN",
                    "criterion": "PTEN expression",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": "overexpression"
                        }
                    ]
                },
                {
                    "exact_snippets": "lack of ARV7 expression",
                    "criterion": "ARV7 expression",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "ki67 =<10%",
                    "criterion": "ki67",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential",
                    "criterion": "contraception use during sex with woman of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "condom use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "use of another effective method of birth control",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug",
                    "criterion": "condom use during sex with pregnant woman",
                    "requirements": [
                        {
                            "requirement_type": "condom use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during study drug"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "donation prohibition",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during study drug"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The methods must consist of a condom and the use of another barrier method (such as a diaphragm or cervical/vault caps) with a spermicidal agent. Your female partner can choose to use an intrauterine device or system (intrauterine device [IUD] or intrauterine system [IUS]) or use birth control pills, injections, or implants instead of a barrier method",
            "criterions": [
                {
                    "exact_snippets": "methods must consist of a condom and the use of another barrier method (such as a diaphragm or cervical/vault caps) with a spermicidal agent",
                    "criterion": "contraceptive method",
                    "requirements": [
                        {
                            "requirement_type": "method type",
                            "expected_value": [
                                "condom",
                                "another barrier method with spermicidal agent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "female partner can choose to use an intrauterine device or system (intrauterine device [IUD] or intrauterine system [IUS])",
                    "criterion": "contraceptive method (female partner)",
                    "requirements": [
                        {
                            "requirement_type": "method type",
                            "expected_value": [
                                "intrauterine device",
                                "intrauterine system"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "female partner can ... use birth control pills, injections, or implants instead of a barrier method",
                    "criterion": "contraceptive method (female partner)",
                    "requirements": [
                        {
                            "requirement_type": "method type",
                            "expected_value": [
                                "birth control pills",
                                "injections",
                                "implants"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Diagnosed congenital bleeding disorders (e.g., von Willebrand's' disease)",
            "criterions": [
                {
                    "exact_snippets": "Diagnosed congenital bleeding disorders (e.g., von Willebrand's' disease)",
                    "criterion": "congenital bleeding disorder",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lithium",
            "criterions": [
                {
                    "exact_snippets": "* Lithium",
                    "criterion": "lithium",
                    "requirements": [
                        {
                            "requirement_type": "exposure or use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery",
            "criterions": [
                {
                    "exact_snippets": "Planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery",
                    "criterion": "planned palliative procedures for bone pain",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place",
            "criterions": [
                {
                    "exact_snippets": "History of Mobitz II second degree or third degree heart block",
                    "criterion": "heart block type",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "Mobitz II second degree",
                                "third degree"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "without a permanent pacemaker in place",
                    "criterion": "permanent pacemaker",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count < 1000/uL at the screening visit",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count < 1000/uL at the screening visit",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1000,
                                "unit": "uL"
                            }
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "screening visit"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe, concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated",
            "criterions": [
                {
                    "exact_snippets": "Severe, concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment",
                    "criterion": "severe concurrent disease, infection, or co-morbidity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "concurrence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator judgment of appropriateness for enrollment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated",
                    "criterion": "medical condition contraindicating corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "prednisone/prednisolone use contraindication",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Congestive heart failure New York Heart Association (NYHA) class 3 or 4 in the past, or history of anthracycline or anthracenedione (mitoxantrone) treatment, unless a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within three months results in a left ventricular ejection fraction that is >= 45%",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure New York Heart Association (NYHA) class 3 or 4 in the past",
                    "criterion": "congestive heart failure (NYHA class)",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "NYHA class"
                            }
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of anthracycline or anthracenedione (mitoxantrone) treatment",
                    "criterion": "anthracycline or anthracenedione (mitoxantrone) treatment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within three months results in a left ventricular ejection fraction that is >= 45%",
                    "criterion": "left ventricular ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "echocardiogram",
                                "multi-gated acquisition scan (MUGA)"
                            ]
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within three months"
                        },
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiation therapy within 3 weeks (if single fraction of radiotherapy within 2 weeks) of enrollment (day 1 visit)",
            "criterions": [
                {
                    "exact_snippets": "Radiation therapy within 3 weeks (if single fraction of radiotherapy within 2 weeks) of enrollment (day 1 visit)",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "single fraction of radiotherapy within 2 weeks",
                    "criterion": "single fraction of radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 4 weeks prior to enrollment (day 1)",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks prior to enrollment (day 1)",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Insulin",
            "criterions": [
                {
                    "exact_snippets": "Insulin",
                    "criterion": "insulin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aminophylline/theophylline",
            "criterions": [
                {
                    "exact_snippets": "Aminophylline/theophylline",
                    "criterion": "aminophylline or theophylline use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)",
            "criterions": [
                {
                    "exact_snippets": "Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)",
                    "criterion": "acquired bleeding disorder",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have used or plan to use from 30 days prior to enrollment (day 1 visit) through the end of the study the following medications known to lower the seizure threshold:",
            "criterions": [
                {
                    "exact_snippets": "Have used or plan to use from 30 days prior to enrollment (day 1 visit) through the end of the study the following medications known to lower the seizure threshold",
                    "criterion": "use of medications known to lower the seizure threshold",
                    "requirements": [
                        {
                            "requirement_type": "usage within time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": -30,
                                        "unit": "days before enrollment"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 0,
                                        "unit": "days after enrollment"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "planned usage during study",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with androgen receptor antagonists (bicalutamide, flutamide, nilutamide), 5-alpha reductase inhibitors (finasteride, dutasteride), estrogens, chemotherapy, or biologic therapy within 4 weeks of enrollment (day 1 visit)",
            "criterions": [
                {
                    "exact_snippets": "Treatment with androgen receptor antagonists (bicalutamide, flutamide, nilutamide) ... within 4 weeks of enrollment (day 1 visit)",
                    "criterion": "treatment with androgen receptor antagonists",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... 5-alpha reductase inhibitors (finasteride, dutasteride) ... within 4 weeks of enrollment (day 1 visit)",
                    "criterion": "treatment with 5-alpha reductase inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... estrogens ... within 4 weeks of enrollment (day 1 visit)",
                    "criterion": "treatment with estrogens",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... chemotherapy ... within 4 weeks of enrollment (day 1 visit)",
                    "criterion": "treatment with chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... biologic therapy within 4 weeks of enrollment (day 1 visit)",
                    "criterion": "treatment with biologic therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of significant bleeding disorder unrelated to cancer, including:",
            "criterions": [
                {
                    "exact_snippets": "History of significant bleeding disorder unrelated to cancer",
                    "criterion": "significant bleeding disorder",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "relation to cancer",
                            "expected_value": "unrelated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pethidine",
            "criterions": [
                {
                    "exact_snippets": "Pethidine",
                    "criterion": "pethidine use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of gastrointestinal (GI) bleeding within one year",
            "criterions": [
                {
                    "exact_snippets": "History of gastrointestinal (GI) bleeding within one year",
                    "criterion": "gastrointestinal (GI) bleeding",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal at the screening visit",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... > 2.5 times the upper limit of normal at the screening visit",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) > 2.5 times the upper limit of normal at the screening visit",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chronically uncontrolled hypertension as indicated by consistently elevated resting blood pressure (systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg) during screening",
            "criterions": [
                {
                    "exact_snippets": "Chronically uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "chronically uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "consistently elevated resting blood pressure (systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg) during screening",
                    "criterion": "resting blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "systolic blood pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 170,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "diastolic blood pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 105,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "consistency",
                            "expected_value": "consistently elevated"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Baseline moderate and severe hepatic impairment (Child Pugh class B & C)",
            "criterions": [
                {
                    "exact_snippets": "Baseline moderate and severe hepatic impairment (Child Pugh class B & C)",
                    "criterion": "hepatic impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        },
                        {
                            "requirement_type": "Child Pugh class",
                            "expected_value": [
                                "B",
                                "C"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin < 9 g/dL at the screening visit at the screening visit",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin < 9 g/dL at the screening visit",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "screening visit"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Atypical antipsychotics (e.g., clozapine, olanzapine, risperidone, ziprasidone)",
            "criterions": [
                {
                    "exact_snippets": "Atypical antipsychotics (e.g., clozapine, olanzapine, risperidone, ziprasidone)",
                    "criterion": "atypical antipsychotic medication use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known metastases to the brain",
            "criterions": [
                {
                    "exact_snippets": "Known metastases to the brain",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active or symptomatic viral hepatitis or chronic liver disease",
            "criterions": [
                {
                    "exact_snippets": "Known active or symptomatic viral hepatitis",
                    "criterion": "viral hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "activity or symptoms",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic liver disease",
                    "criterion": "chronic liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of another malignancy within the previous 2 years with > 30 % probability of relapse other than curatively treated non-melanomatous skin cancer",
            "criterions": [
                {
                    "exact_snippets": "History of another malignancy within the previous 2 years",
                    "criterion": "history of another malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "> 30 % probability of relapse",
                    "criterion": "probability of relapse of another malignancy",
                    "requirements": [
                        {
                            "requirement_type": "probability of relapse",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "other than curatively treated non-melanomatous skin cancer",
                    "criterion": "type of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "curatively treated non-melanomatous skin cancer"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bupropion",
            "criterions": [
                {
                    "exact_snippets": "Bupropion",
                    "criterion": "bupropion use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled angina within 6 months",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled angina within 6 months",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine (Cr) > 2 mg/dL at the screening visit",
            "criterions": [
                {
                    "exact_snippets": "Creatinine (Cr) > 2 mg/dL at the screening visit",
                    "criterion": "serum creatinine level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the screening visit"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Myocardial infarction within 6 months",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction within 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of an investigational agent within 4 weeks of enrollment (day 1)",
            "criterions": [
                {
                    "exact_snippets": "Use of an investigational agent within 4 weeks of enrollment (day 1)",
                    "criterion": "use of investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant cardiovascular disease including:",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hypotension (systolic blood pressure < 86 millimeters of mercury or bradycardia with a heart rate of < 50 beats per minute on any ECG taken at the screening visit",
            "criterions": [
                {
                    "exact_snippets": "Hypotension (systolic blood pressure < 86 millimeters of mercury",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 86,
                                "unit": "millimeters of mercury"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bradycardia with a heart rate of < 50 beats per minute on any ECG taken at the screening visit",
                    "criterion": "heart rate",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "beats per minute"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of pituitary or adrenal dysfunction",
            "criterions": [
                {
                    "exact_snippets": "Known history of pituitary ... dysfunction",
                    "criterion": "pituitary dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known history of ... adrenal dysfunction",
                    "criterion": "adrenal dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)",
            "criterions": [
                {
                    "exact_snippets": "History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)",
                    "criterion": "ventricular arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: patients may not have received any growth factors or blood transfusions within seven days of the hematologic laboratory values obtained at the screening visit",
            "criterions": [
                {
                    "exact_snippets": "patients may not have received any growth factors ... within seven days of the hematologic laboratory values obtained at the screening visit",
                    "criterion": "growth factor administration",
                    "requirements": [
                        {
                            "requirement_type": "absence within time window",
                            "expected_value": {
                                "operator": "<",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients may not have received any ... blood transfusions within seven days of the hematologic laboratory values obtained at the screening visit",
                    "criterion": "blood transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence within time window",
                            "expected_value": {
                                "operator": "<",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of seizure or any condition that may increase the patient's seizure risk. Also, history of loss of consciousness or transient ischemic attack within 12 months of day 1",
            "criterions": [
                {
                    "exact_snippets": "History of seizure",
                    "criterion": "seizure",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any condition that may increase the patient's seizure risk",
                    "criterion": "condition increasing seizure risk",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of loss of consciousness",
                    "criterion": "loss of consciousness",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... transient ischemic attack within 12 months of day 1",
                    "criterion": "transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count =< 100,000 x 10^9/uL at the screening visit",
            "criterions": [
                {
                    "exact_snippets": "Platelet count =< 100,000 x 10^9/uL at the screening visit",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 100000,
                                "unit": "x 10^9/uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Structurally unstable bone lesions suggesting impending fracture",
            "criterions": [
                {
                    "exact_snippets": "Structurally unstable bone lesions",
                    "criterion": "bone lesions",
                    "requirements": [
                        {
                            "requirement_type": "structural stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "suggesting impending fracture",
                    "criterion": "bone lesions",
                    "requirements": [
                        {
                            "requirement_type": "risk of impending fracture",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prolonged corrected QT interval by the Fridericia correction formula (QTcF) on the screening electrocardiogram (ECG) > 470 msec",
            "criterions": [
                {
                    "exact_snippets": "Prolonged corrected QT interval by the Fridericia correction formula (QTcF) on the screening electrocardiogram (ECG) > 470 msec",
                    "criterion": "corrected QT interval (QTcF) on screening ECG",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin (Tbili) > 1.5 times the upper limit of normal at the screening visit",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin (Tbili) > 1.5 times the upper limit of normal at the screening visit",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known allergy to the study drugs or any of its components",
            "criterions": [
                {
                    "exact_snippets": "Known allergy to the study drugs or any of its components",
                    "criterion": "allergy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "allergen",
                            "expected_value": [
                                "study drugs",
                                "any of its components"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phenothiazine antipsychotics (e.g., prochlorperazine [compazine], chlorpromazine, mesoridazine, thioridazine)",
            "criterions": [
                {
                    "exact_snippets": "Phenothiazine antipsychotics (e.g., prochlorperazine [compazine], chlorpromazine, mesoridazine, thioridazine)",
                    "criterion": "phenothiazine antipsychotic use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tricyclic and tetracyclic antidepressants (e.g., amitriptyline, desipramine, doxepin, imipramine, maprotiline, mirtazapine)",
            "criterions": [
                {
                    "exact_snippets": "Tricyclic and tetracyclic antidepressants (e.g., amitriptyline, desipramine, doxepin, imipramine, maprotiline, mirtazapine)",
                    "criterion": "tricyclic and tetracyclic antidepressant use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug_names",
                            "expected_value": [
                                "amitriptyline",
                                "desipramine",
                                "doxepin",
                                "imipramine",
                                "maprotiline",
                                "mirtazapine"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gastrointestinal disorder affecting absorption (e.g., gastrectomy)",
            "criterions": [
                {
                    "exact_snippets": "Gastrointestinal disorder affecting absorption",
                    "criterion": "gastrointestinal disorder affecting absorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "gastrectomy",
                    "criterion": "gastrectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Bradycardia with a heat rate of < 50 beats per minutes in the screening ECG, unless pharmaceutically induced and reversible",
            "criterions": [
                {
                    "exact_snippets": "Bradycardia with a heart rate of < 50 beats per minutes in the screening ECG",
                    "criterion": "heart rate",
                    "requirements": [
                        {
                            "requirement_type": "measurement",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "beats per minute"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "in the screening ECG"
                        }
                    ]
                },
                {
                    "exact_snippets": "unless pharmaceutically induced and reversible",
                    "criterion": "bradycardia etiology",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "not pharmaceutically induced"
                        },
                        {
                            "requirement_type": "reversibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior use of ketoconazloe, enzalutamide, abiraterone or apalutamide or participation in a previous clinical trial of ketoconazloe,enzalutamide, abiraterone or apalutamide unless within the neoadjuvant setting",
            "criterions": [
                {
                    "exact_snippets": "Prior use of ketoconazloe, enzalutamide, abiraterone or apalutamide",
                    "criterion": "prior use of ketoconazloe, enzalutamide, abiraterone, or apalutamide",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participation in a previous clinical trial of ketoconazloe, enzalutamide, abiraterone or apalutamide",
                    "criterion": "participation in previous clinical trial of ketoconazloe, enzalutamide, abiraterone, or apalutamide",
                    "requirements": [
                        {
                            "requirement_type": "history of participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless within the neoadjuvant setting",
                    "criterion": "setting of prior use or trial participation",
                    "requirements": [
                        {
                            "requirement_type": "setting",
                            "expected_value": "neoadjuvant"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}